Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Consortia: CMAI
Lowe JR, Perry DJ, Salama AK, Mathews CE, Moss LG, Hanks BA.
J Immunother Cancer. 2016 Dec 20;4:89. doi: 10.1186/s40425-016-0196-z. PMID: 28031819